Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Trial Profile

Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs HPRL G129R (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man
  • Acronyms ProlantaOC
  • Sponsors Oncolix
  • Most Recent Events

    • 08 Jan 2018 According to an Oncolix media release, The first cohort, treated with the lowest dose, was completed.
    • 08 Jan 2018 According to an Oncolix media release, patient recruitment for the second dosing group of this trial has been initiated. Dosing is anticipated to begin during the first quarter of 2018 and to complete dosing prior to the end of the year
    • 03 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top